Biotech RadarJobs updated

COMPANY

Frontera Therapeutics

fronteratherapeutics.com ↗

Clinical Phase 2

Keywords: cardiovascular rare disease ophthalmology gene therapy AAV rare diseases Diabetic Macular Edema Neovascular Age-related Macular Degeneration X-Linked Retinitis Pigmentosa Biallelic RPE65 Mutation-associated Retinal Dystrophy FT-003 FT-002

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

  1. Trial start Phase 1/Phase 2: Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa source ↗
  2. Trial start Phase 1/Phase 2: Gene Therapy for DME source ↗
  3. Trial start Phase 1/Phase 2: Gene Therapy(FT-003) for Wet AMD source ↗
  4. Trial start Phase 1: Gene Therapy for Diabetic Macular Edema source ↗
  5. Trial start Phase 1: Gene Therapy for Wet AMD source ↗
  6. Trial start Early phase 1: Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa source ↗
  7. Trial start Phase 1/Phase 2: Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy source ↗

Clinical trials (lead sponsor) 7

RecordTitlePhaseStatusStartPrimary completion
NCT06492850Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis PigmentosaPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Apr 1, 2024Aug 1, 2025 (estimated)
NCT06492876Gene Therapy for DMEPhase 1/Phase 2RecruitingNov 15, 2023Nov 15, 2024 (estimated)
NCT06492863Gene Therapy(FT-003) for Wet AMDPhase 1/Phase 2RecruitingAug 15, 2023Oct 15, 2024 (estimated)
NCT05916391Gene Therapy for Diabetic Macular EdemaPhase 1RecruitingMay 19, 2023May 1, 2025 (estimated)
NCT05874310Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis PigmentosaEarly phase 1RecruitingFeb 1, 2023Oct 31, 2023 (estimated)
NCT05858983Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal DystrophyPhase 1/Phase 2RecruitingNov 30, 2022Nov 30, 2025 (estimated)
NCT05611424Gene Therapy for Wet AMDPhase 1Not yet recruitingMay 1, 2023Nov 30, 2024 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback